Sinovac Biotech
China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialisation of vaccines.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
$86.7m | Post IPO Equity | ||
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 32 % | 7 % | 108 % | 3694 % | (92 %) | (70 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 30 % | 23 % | 31 % | 44 % | 91 % | 13 % | 16 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 15 % | 9 % | 18 % | 22 % | 44 % | 8 % | (22 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 12 % | 10 % | 10 % | 10 % | 1 % | 30 % | 77 % |
Source: Company filings or news article
Related Content
Sinovac Biotech Ltd. is a leading biopharmaceutical company specializing in the research, development, and commercialization of vaccines to prevent and control infectious diseases. The company serves a global market, focusing on both domestic and international clients, including governments, healthcare providers, and research institutions. Sinovac's business model revolves around leveraging cutting-edge technology and strategic partnerships with renowned universities and research institutes to develop high-quality vaccines. Revenue is primarily generated through the sale of vaccines and licensing agreements for technology and virus strains. The company has successfully developed vaccines for SARS, avian influenza H5N1, H1N1 influenza, and hand, foot, and mouth disease, among others. Sinovac continues to innovate and expand its product portfolio to address newly emerging infectious diseases.
Keywords: vaccines, infectious diseases, biopharmaceutical, research, development, commercialization, global market, strategic partnerships, technology, licensing.
